Skip to main content

Novartis AG (NOVN) Gets a Sell from Goldman Sachs

Tipranks - Tipranks - Thu Feb 5, 3:30AM CST

Goldman Sachs analyst James Quigley maintained a Sell rating on Novartis AG today and set a price target of CHF104.00.

Claim 50% Off TipRanks Premium

Quigley covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and Sanofi. According to TipRanks, Quigley has an average return of -6.4% and a 41.61% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novartis AG with a CHF115.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion. In comparison, last year the company earned a revenue of CHF13.17 billion and had a net profit of CHF3.19 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).